Trianglesilevertinib in combination with… (NCT07326566)
silevertinib in combination with temozolomide trial for Glioblastoma (GBM) (NCT07326566). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed IDH-wild-type glioblastoma, without progression after resection and chemoradiation. The randomized part requires EGFRvIII and an unmethylated MGMT promoter; the safety lead-in permits other EGFR alterations.
The idea: add silevertinib, which blocks EGFR growth signaling, to DNA-damaging temozolomide. After dose selection, patients receive both oral drugs or temozolomide alone. Temozolomide runs for up to six cycles.
This phase 2 study plans 162 patients. Black Diamond Therapeutics sponsors it, with 35 recruiting US sites. Planned Optune use is excluded.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.